Diadia
Our TechnologyResourcesAboutLoginBook a call

© 2026 Diadia. All rights reserved.

About UsOur TechnologyResearchResources
Privacy Policy
SupportBook a callLogin
Health Privacy Policy
InstagramFacebookLinkedInX (formerly Twitter)
Terms and Conditions
About UsOur TechnologyResearchResources
Privacy Policy
SupportBook a callLogin
Health Privacy Policy
InstagramFacebookLinkedInX (formerly Twitter)
Terms and Conditions

© 2026 Diadia. All rights reserved.

←Transparency Reports

metabolic · Mechanism Report

Does LDL receptor activity clear ApoB-containing LDL particles and lower LDL-related markers?

LDL receptor activity clears ApoB-containing LDL particles, while reduced activity raises LDL cholesterol, non-HDL cholesterol, ApoB, and LDL particle number.

PlausibleJuly 30, 202618 Sources

Reasoning Paths

Each route from condition to outcome carries a support score — the product of its edge weights. Select one to isolate it on the figure.

This is what AI claimed

The LDL receptor clears ApoB-containing LDL particles from circulation, and reduced LDL receptor activity raises LDL cholesterol, non-HDL cholesterol, ApoB, and LDL particle number.

laying out figure…
0 of 2 paths supported
UnsupportedPlausibleSupported

How to read the figure

Evidence state

  • ●EstablishedStrong, replicated evidence.
  • ◐ModerateEvidence-informed; limited or moderate.
  • ◇PlausibleMechanistically coherent, not established.
  • ✕UnsupportedTested and not supported — link breaks.
  • ?MissingNo evidence either way — untested.

Node shapes

  • BiomarkerA measurable state — a lab value, hormone, or genetic factor.
  • ProcessA biological process, pathway, or mechanism step.
  • ConditionA condition, exposure, intervention, or symptom.
  • OutcomeThe endpoint the claim leads to.

Executive summary

The claim describes LDLR as the main pathway for removing ApoB-containing LDL from circulation. It also frames reduced receptor activity as leading to slower clearance and higher circulating LDL-related biomarkers. The mechanism graph supports this through receptor-mediated uptake, endosomal release, and receptor recycling.

Verified conclusion

The low-density lipoprotein receptor (LDLR) serves as the primary gateway for clearing atherogenic apolipoprotein B (ApoB)-containing lipoproteins from circulation. This highly efficient pathway directly governs systemic lipid homeostasis.

Receptor-ligand dynamics and cellular recycling

  • High-affinity binding: At physiological pH (~7.4), hepatic LDLR binds to the ApoB-100 ligand on LDL particles with a dissociation constant ($K_d$) of approximately 3–5 nM.
  • Clathrin-mediated internalization: The LDLR-ApoB complex clusters into clathrin-coated pits, driven by the cytoplasmic NPxY sorting signal, and is internalized into early sorting endosomes.
  • pH-dependent recycling: Inside the endosomal lumen, the pH drops to ~6.0. This acidification triggers a conformational change in LDLR (forming a closed hairpin structure) that reduces its affinity for ApoB-100, prompting ligand dissociation. The LDL particle is routed to lysosomes for degradation, while the freed LDLR recycles back to the cell surface—a complete cycle taking just 10–15 minutes.

Systemic consequences of impaired LDLR activity

  • Prolonged particle residence: When hepatic LDLR activity is compromised (as in familial hypercholesterolemia), the fractional clearance rate of ApoB-containing particles drops, extending their plasma residence time to several days.
  • Stoichiometric lipid elevation: Because each LDL particle contains exactly one ApoB-100 molecule, reduced clearance causes parallel elevations in ApoB concentrations and LDL particle number (LDL-P). This accumulation directly drives up circulating LDL cholesterol (LDL-C) and non-HDL cholesterol (non-HDL-C).

Bottom line

  • The LDLR pathway is the primary regulator of systemic atherogenic lipoproteins. Impaired LDLR clearance or recycling directly escalates LDL-C, non-HDL-C, ApoB, and LDL-P, while upregulating this receptor-driven cycle remains the most effective therapeutic mechanism to lower circulating particle concentrations.

References

  1. Complete Deficiency of the Low-Density Lipoprotein Receptor Is Associated With Increased Apolipoprotein B-100 Production | Arteriosclerosis, Thrombosis, and Vascular Biology — ahajournals.org ↗
  2. Pathways and Molecular Mechanisms Governing LDL Receptor Regulation | Circulation Research — ahajournals.org ↗
  3. Biochemistry, LDL Cholesterol - StatPearls - NCBI Bookshelf - NIH — ncbi.nlm.nih.gov ↗
  4. Mechanism of LDL binding and release probed by structure-based ... — pmc.ncbi.nlm.nih.gov ↗
  5. Familial defective apolipoprotein B-100: low density lipoproteins with abnormal receptor binding. — pnas.org ↗
  6. Familial Hypercholesterolemia - StatPearls - NCBI Bookshelf — ncbi.nlm.nih.gov ↗
  7. Familial Hypercholesterolemia: Genes and Beyond — ncbi.nlm.nih.gov ↗
  8. Hypercholesterolemia - StatPearls - NCBI Bookshelf - NIH — ncbi.nlm.nih.gov ↗
  9. Low-Density Lipoprotein Receptor (LDLR) Family ... - PMC — pmc.ncbi.nlm.nih.gov ↗
  10. The role of the LDL receptor in apolipoprotein B secretion. — pmc.ncbi.nlm.nih.gov ↗
  11. Presence and type of low density lipoprotein receptor (LDLR) mutation influences the lipid profile and response to lipid-lowering therapy in Brazilian patients with heterozygous familial hypercholesterolemia - PubMed — pubmed.ncbi.nlm.nih.gov ↗
  12. Familial Hypercholesterolemia: From Clinical Suspicion to ... — pmc.ncbi.nlm.nih.gov ↗
  13. Molecule of the Month: Apolipoprotein B-100 and LDL Receptor - PDB-101 — pdb101.rcsb.org ↗
  14. Role of an Intramolecular Contact on Lipoprotein Uptake by the LDL ... — pmc.ncbi.nlm.nih.gov ↗
  15. The Epidermal Growth Factor Homology Domain of the LDL ... — pmc.ncbi.nlm.nih.gov ↗
  16. Structural changes induced by acidic pH in human apolipoprotein B-100 — pmc.ncbi.nlm.nih.gov ↗
  17. Versatility in ligand recognition by LDL receptor family proteins: advances and frontiers. — pmc.ncbi.nlm.nih.gov ↗
  18. [PDF] Structure of the LDL Receptor Extracellular Domain at Endosomal pH — mcgill.ca ↗

See a full patient report verified like this

Book a walkthrough

Related Claims

Plausible8 sourcesDoes the MTHFR rs1801131 A1298C variant mildly reduce enzyme activity and have a smaller homocysteine effect than C677T?→Plausible3 sourcesIs TMAO formed from gut microbial conversion of choline and carnitine followed by liver oxidation?→